TY - JOUR
T1 - Long-term proton pump inhibitor use and gastrointestinal cancer
AU - Graham, David Y.
AU - Genta, Robert M.
N1 - Funding Information:
This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Veterans Administration or the National Institutes of Health.
Funding Information:
Dr. Genta has been a consultant for AstraZeneca and TAP Pharmaceutical Products, and has received grants from Otsuka Pharmaceuticals. Currently he receives no industry support and is an employee of the Office for Veterans Affairs and Caris Diagnostics, Irving, Texas.
PY - 2008
Y1 - 2008
N2 - Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.
AB - Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.
UR - http://www.scopus.com/inward/record.url?scp=60749113725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60749113725&partnerID=8YFLogxK
U2 - 10.1007/s11894-008-0100-1
DO - 10.1007/s11894-008-0100-1
M3 - Review article
C2 - 19006608
AN - SCOPUS:60749113725
SN - 1522-8037
VL - 10
SP - 543
EP - 547
JO - Current gastroenterology reports
JF - Current gastroenterology reports
IS - 6
ER -